Ncleax is a biopharmaceutical company focused on the treatment of neuropathic pain.

It uses a new injectable drug called nceps which is currently approved in the US to treat certain types of neuropathy. 

In October, the FDA approved ncep as a treatment for the most common form of neurotic pain in adults, but only for a year, in order to allow it to reach the wider population.

It has also been approved in Europe, where it is already approved, and will soon be approved in China.

The drug, known as Nceps, is an injectable device that contains a tiny capsule containing two types of nanoparticles, known in industry parlance as nucleic acids.

Ncep is manufactured by the Bristol-Myers Squibb (BMY) biotechnology company.

In the US, it is marketed under the trade name “NCEP-1”, and in Europe it is also marketed under “Nceps-A”.BMY is one of the world’s largest pharmaceutical companies, and has a large number of suppliers, such as the US Food and Drug Administration (FDA), the European Medicines Agency (EMA) and the UK Medicines and Healthcare Products Regulatory Agency (MHRA).

In February, the MHRA said it was considering a ban on sales of NcePs to people under the age of 35.

In May, the UK government announced a new regulatory framework for NcePS, which aims to make it easier for manufacturers to access the drug in the UK.

The NCEP injectable is a “tentacle” of the biotechnology industry, with a tiny plastic tube that is injected into a vein and then released through a needle.

The needle, which is usually shaped like a needle, is used to inject a drug into a person’s bloodstream.

The device is used for treating pain caused by nerve damage, infection, tumors, infections, autoimmune diseases, and even pain caused to the joints.

The needle is designed to deliver the drug to the nerves and to deliver it to a target site, in this case the nerve.

The drug is then delivered through the bloodstream to a site known as the spinal cord, which connects the brain to the muscles. 

NCEPs are usually used to treat neuropathic symptoms, including pain, numbness and tingling.

They are not approved for treating other conditions, including HIV, heart disease or depression.

In November, the NCEPs manufacturer, Bristol-Meyers Squebb, said the drug would be available by March 2018.

In January, the company said it would begin marketing the drug, but it has yet to start marketing Nceeps in the United States.BMY did not respond to requests for comment from New Scientist.